Two medications have fundamentally changed the conversation around weight loss: semaglutide and tirzepatide. Both are injectable peptides prescribed by physicians, both produce meaningful weight loss, and both work by influencing the hormones that regulate hunger and metabolism. But they're not the same — and choosing between them isn't a coin flip.
This article breaks down the science behind each, compares the clinical evidence, and helps you understand which one may be the better fit depending on your health history and goals.
How They Work: One Mechanism vs. Two
The key difference between semaglutide and tirzepatide comes down to how many hormonal pathways each targets.
Semaglutide: GLP-1 Agonist
Semaglutide mimics a gut hormone called GLP-1 (glucagon-like peptide-1). GLP-1 is released after you eat and signals your brain that you're full. It also slows the rate at which your stomach empties, so food stays in your system longer — reducing appetite and overall calorie intake. Semaglutide was originally developed for type 2 diabetes and later approved for weight management at a higher dose.
Tirzepatide: GLP-1 + GIP Dual Agonist
Tirzepatide activates two receptors: GLP-1 (same as semaglutide) and GIP (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone that plays a role in fat storage, insulin sensitivity, and how your body processes nutrients. By hitting both receptors simultaneously, tirzepatide appears to produce a more powerful metabolic effect than either hormone could on its own — a synergy researchers call "twincretin" action.
Think of semaglutide as a single key that unlocks one metabolic door. Tirzepatide uses two keys at once — opening both the GLP-1 and GIP pathways for a broader effect on appetite, fat storage, and insulin sensitivity.
What the Clinical Trials Show
Both peptides have been studied in large, rigorous clinical trials comparing them to placebo in people with obesity.
Semaglutide: The STEP Trials
The STEP program (Semaglutide Treatment Effect in People with obesity) ran several Phase 3 trials. In STEP 1, participants on semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. About one-third of participants lost more than 20% of their body weight.
Tirzepatide: The SURMOUNT Trials
The SURMOUNT trials tested tirzepatide at three doses (5 mg, 10 mg, 15 mg). In SURMOUNT-1, participants on the highest dose lost an average of 20.9% of body weight over 72 weeks — nearly double the results seen with semaglutide. At least 57% of participants on the top dose lost more than 20% of their body weight.
| Metric | Semaglutide (STEP 1) | Tirzepatide (SURMOUNT-1, 15mg) |
|---|---|---|
| Average Weight Loss | ~14.9% | ~20.9% |
| % Losing >20% Body Weight | ~33% | ~57% |
| Trial Duration | 68 weeks | 72 weeks |
| Injection Frequency | Once weekly | Once weekly |
| FDA Approval (Weight) | Yes (2021) | Yes (2023) |
Side Effects: How Do They Compare?
Both medications share a similar side effect profile because both activate the GLP-1 pathway. The most common issues are gastrointestinal (GI) — nausea, vomiting, diarrhea, and constipation. These are typically worst when starting or increasing the dose and tend to improve over time.
Nausea
Most common side effect for both. Usually peaks in first 4–8 weeks, then fades.
Reduced Appetite
Desired effect, but can be too strong initially — protein intake matters.
Fatigue
Some patients feel low energy early on, especially with calorie restriction.
Injection Site
Mild redness or discomfort at the injection site; both are subcutaneous injections.
In head-to-head trial data, tirzepatide showed similar or slightly higher rates of GI side effects compared to semaglutide — likely because of its stronger overall effect. However, tirzepatide appeared to cause slightly less nausea at equivalent doses. Both medications carry a rare risk of pancreatitis and should not be used by people with a personal or family history of medullary thyroid carcinoma.
Who Is Each Medication Best For?
Semaglutide may be right for you if:
- You have 20–40 lbs to lose and want a well-established option with years of real-world data
- You have a history of sensitivity to GI side effects and want to start with a single-mechanism drug
- You're managing type 2 diabetes (lower-dose semaglutide has more extensive diabetes data)
- Cost is a primary concern (semaglutide compounding is typically slightly less expensive)
Tirzepatide may be right for you if:
- You have significant weight to lose (50+ lbs) and want the strongest available option
- You have insulin resistance, prediabetes, or metabolic syndrome — the GIP pathway adds meaningful metabolic benefit
- You've tried semaglutide and hit a plateau — tirzepatide often produces additional weight loss
- You want the most clinically proven weight loss results currently available
Cost and Availability
Brand-name versions of both medications (Ozempic/Wegovy for semaglutide; Mounjaro/Zepbound for tirzepatide) can cost $800–$1,400/month without insurance. Compounded versions through licensed pharmacies are significantly more affordable — often $200–$400/month — and are available through telehealth providers like PeptidesRx when prescribed by a licensed physician.
PeptidesRx works with licensed U.S. compounding pharmacies that meet FDA quality standards. Both compounded semaglutide and tirzepatide are available with a valid prescription from one of our providers.
Frequently Asked Questions
Can I switch from semaglutide to tirzepatide?
Yes. Many patients transition after reaching a plateau on semaglutide. Your provider will determine the appropriate starting dose for tirzepatide based on your current dose and how long you've been on semaglutide.
Do I have to inject both medications?
Both semaglutide and tirzepatide are currently available as subcutaneous (under-the-skin) injections administered once per week. An oral form of semaglutide exists (Rybelsus), but it's only FDA-approved for diabetes management at lower doses.
What happens if I stop taking them?
Clinical trials show that most people regain a significant portion of lost weight after stopping. These medications work as long as you take them — they're not a cure. Lifestyle changes alongside medication improve long-term outcomes.
Is tirzepatide always better than semaglutide?
On average in clinical trials, tirzepatide produces more weight loss. But individual responses vary. Some patients do exceptionally well on semaglutide, and starting with a single-mechanism drug is reasonable — especially if you're sensitive to side effects.